201 related articles for article (PubMed ID: 2189835)
1. Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia.
Chan MK; Varghese Z; Li MK; Wong WS; Li CS
Int J Artif Organs; 1990 Mar; 13(3):162-8. PubMed ID: 2189835
[TBL] [Abstract][Full Text] [Related]
2. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
[TBL] [Abstract][Full Text] [Related]
3. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
[TBL] [Abstract][Full Text] [Related]
4. Quantitative bone scanning in the diagnosis of aluminium osteomalacia.
Worth DP; Smye SW; Robinson PJ; Davison AM; Will EJ
Nephrol Dial Transplant; 1989; 4(8):721-4. PubMed ID: 2510081
[TBL] [Abstract][Full Text] [Related]
5. Serum aluminium level in the veneto chronic haemodialysis population: cross-sectional study on 1,026 patients.
Piccoli A; Andriani M; Mattiello G; Nordio M; Modena F; Dalla Rosa C
Nephron; 1989; 51(4):482-90. PubMed ID: 2787000
[TBL] [Abstract][Full Text] [Related]
6. [Detecting and evaluating hyperaluminemia in 3 dialysis centers].
Balabán D; Simícková J; Kubátko J; Syrovátka P
Cas Lek Cesk; 1989 Dec; 128(51):1611-4. PubMed ID: 2631999
[TBL] [Abstract][Full Text] [Related]
7. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption.
Heaf JG; Pødenphant J; Andersen JR
Nephron; 1986; 42(3):210-6. PubMed ID: 3945361
[TBL] [Abstract][Full Text] [Related]
8. Value of serum aluminium monitoring in dialysis patients: a multicentre study.
D'Haese PC; Clement JP; Elseviers MM; Lamberts LV; Van de Vyver FL; Visser WJ; De Broe ME
Nephrol Dial Transplant; 1990; 5(1):45-53. PubMed ID: 2109284
[TBL] [Abstract][Full Text] [Related]
9. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
[TBL] [Abstract][Full Text] [Related]
10. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
Jarava C; Armas JR; Palma A
Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
[TBL] [Abstract][Full Text] [Related]
11. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
Heaf JG; Nielsen LP
Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
[TBL] [Abstract][Full Text] [Related]
12. Correction of high serum aluminium in a patient on maintenance haemodialysis.
Wallace MR
N Z Med J; 1981 May; 93(684):335-7. PubMed ID: 6942294
[TBL] [Abstract][Full Text] [Related]
13. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium.
Ward MK; Feest TG; Ellis HA; Parkinson IS; Kerr DN
Lancet; 1978 Apr; 1(8069):841-5. PubMed ID: 76795
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
15. Silicon and aluminium interactions in haemodialysis patients.
Parry R; Plowman D; Delves HT; Roberts NB; Birchall JD; Bellia JP; Davenport A; Ahmad R; Fahal I; Altmann P
Nephrol Dial Transplant; 1998 Jul; 13(7):1759-62. PubMed ID: 9681724
[TBL] [Abstract][Full Text] [Related]
16. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V
Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354
[TBL] [Abstract][Full Text] [Related]
17. Radiography of healing dialysis osteodystrophy.
Barmeir E; Dubowitz B; Hudson GA; Milne FJ; Meyers AM
Acta Radiol Diagn (Stockh); 1984; 25(2):107-12. PubMed ID: 6375266
[TBL] [Abstract][Full Text] [Related]
18. Iatrogenic osteomalacia and myopathy due to phosphate depletion.
Baker LR; Ackrill P; Cattell WR; Stamp TC; Watson L
Br Med J; 1974 Jul; 3(5924):150-2. PubMed ID: 4843652
[TBL] [Abstract][Full Text] [Related]
19. Dialysate aluminium concentration and renal bone disease.
Walker GS; Aaron JE; Peacock M; Robinson PJ; Davison AM
Kidney Int; 1982 Feb; 21(2):411-5. PubMed ID: 7070002
[TBL] [Abstract][Full Text] [Related]
20. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
